Actively Recruiting
Value of Screening MRI Brain in Patients With Newly Diagnosed Stage IV Non-oncogene Addicted Non-small Cell Lung Cancer - The VULCAN Trial
Led by University Medical Center Groningen · Updated on 2024-05-23
100
Participants Needed
1
Research Sites
43 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients with newly diagnosed stage IV non-oncogene addicted non-small cell lung cancer (NSCLC) who are fit for systemic treatment and show no symptoms of brain disease. The study aims to evaluate the clinical value of performing a brain MRI scan as a screening tool in this patient group. This research is sponsored by the University Medical Center Groningen and focuses on using MRI to detect brain involvement up to six months after the scan. Participants will undergo an MRI scan of the brain as the main diagnostic test. This MRI is used to screen for brain disease in patients meeting the criteria. There is no comparison group or placebo; the focus is on the screening population only. The study assesses the impact and usefulness of the MRI scan results in this stage IV NSCLC population. During the study, participants will be monitored for up to six months after the MRI. Researchers will evaluate the clinical outcomes related to the MRI findings. Patients will be assessed according to standard clinical care, including physical status and symptoms. The total study duration and follow-up are designed to measure the value of brain MRI screening for these patients, including any changes or developments noted after the scan.
CONDITIONS
Brief Title
Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
- Fit for systemic treatment (PS 0-2) according to standard of care.
- No symptoms of brain disease assessed by the thoracic oncologist according to standard clinical care.
You will not qualify if you...
- Prior or concurrent therapy for stage IV disease.
- Presence of oncogenic driver mutations such as EGFR, ALK, ROS1, RET, MET, or BRAF with approved targeted treatments.
- Contraindications for MRI scan with contrast according to institutional protocols.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants undergo an MRI scan of the brain to assess for brain disease.
1 visit (in-person)
Duration - Up to 6 months
Participants are observed for up to 6 months after the MRI to evaluate clinical outcomes.
Trial Site Locations
Total: 1 location
1
University Medical Center Groningen
Groningen, Netherlands, 9713LZ
Actively Recruiting
Research Team
F
F. Bensch, MD, PhD
L
L.B.M. Hijmering, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here